Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.

Abstract:

BACKGROUND:The discovery of two immunoglobulin G (IgG) antibodies against aquaporin 4 (anti-AQP4) and myelin oligodendrocyte glycoprotein (anti-MOG) has led to the distinction of the disorders anti-AQP4 immunoglobulin G positive neuromyelitis spectrum disorder (AQP4-IgG+ NMOSD) and anti-MOG associated disorder (MOGAD). Different clinical and radiological features have been proposed to distinguish these two demyelinating CNS diseases. METHODS:This is a single-center retrospective review at the University of Florida (UF) including all patients with the diagnostic code ICD G36 ("other acute disseminated demyelination") from October 2015 to January 2020 (n=141) and all charts included in the clinical NMOSD database of the UF Division of Neuroimmunology (n=36). A total of 151 cases were reviewed for presence of anti-MOG and anti-AQP4 antibodies and NMOSD diagnostic criteria. Differences in MOGAD and AQP4-IgG+ NMOSD were compared. RESULTS:Of the 151 reviewed patient charts, 11 were consistent with MOGAD and 43 with AQP4-IgG+ NMOSD. Patients with MOGAD were significantly younger at symptom onset compared to patients with AQP4-IgG+ NMOSD (14 [1-33] years vs. 37 [6-82] years; p=0.005). In comparison with AQP4-IgG+ NMOSD, optic neuritis in MOGAD was more frequently associated with bilateral optic nerve involvement: (6/11 [54.5%] vs. 6/43 [13.9%]; p=0.009) and fundoscopic presence of optic disc edema (5/11 [45.5%] vs. 3/43 [7%]; p=0.006). Perineuritis was a common radiological feature in MOGAD (present in 4 cases). In case of myelitis, there was more frequent involvement of the conus medullaris in MOGAD (4/11 [36.4%] vs. 2/43 [4.7%]; p=0.012). Symptomatic cerebral syndrome with supratentorial white matter lesions was seen in MOGAD patients with pediatric onset (pediatric onset: 4/6 [66.7%] vs. adult onset: 0/5 [0%]. In MOGAD, evidence for combined central and peripheral demyelination and increased intracranial pressure was present in one patient each. A preceding inciting event (illness/postpartum) was more frequently identifiable in MOGAD (4/11 [36.4%] vs. 4/43 [7%]; p=0.045). Disability as calculated on the Expanded Disability Status Scale was less severe in MOGAD compared to AQP-IgG+ NMOSD (most severe presentation: 5 [2-7] vs. 7 [1-10]; p=0.015; most recent assessment: 2 [0-5] vs. 5 [0-10]; p=0.045) and patients were more likely to respond to treatment of acute attacks with corticosteroids and/or plasmapheresis (Clinical Global Impression-Global Change scale: 1 [1-4] vs. 3 [1-6]; p=0.001). INTERPRETATION:The study confirms that simultaneous bilateral optic neuritis, presence of optic disc edema, transverse myelitis with conus involvement and a less severe disease course are distinctive features of MOGAD.

authors

Rempe T,Tarhan B,Rodriguez E,Viswanathan VT,Gyang TV,Carlson A,Tuna IS,Rees J

doi

10.1016/j.msard.2020.102718

subject

Has Abstract

pub_date

2020-12-24 00:00:00

pages

102718

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(20)30792-6

journal_volume

48

pub_type

杂志文章
  • Coexistent MOG, NMDAR, CASPR2 antibody positivity: Triumph over the triumvirate.

    abstract::Myelin oligodendrocyte glycoprotein (MOG) antibody (MOG -Ab) positive cases can have a focal encephalitis like presentation. Many reports of anti N-methyl-D-aspartate receptor (NMDAR) encephalitis have documented simultaneous coexistence of MOG-Ab which is explained by the coexpression of NMDA receptors and MOG on oli...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102468

    authors: Cherian A,Divya KP,Shetty SC,Kannoth S,Thomas B

    更新日期:2020-11-01 00:00:00

  • Worsening of disability caused by relapses in multiple sclerosis: A different approach.

    abstract:BACKGROUND:In multiple sclerosis (MS) the quantitative role of relapses in Expanded Disability Status Scale (EDSS) worsening beyond the recovery phase is not well known. Most studies have examined the predictive role of early relapses in more distant endpoints. Relapses and worsening may be associated because they coul...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.04.017

    authors: Koch-Henriksen N,Thygesen LC,Sørensen PS,Magyari M

    更新日期:2019-07-01 00:00:00

  • Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review.

    abstract:BACKGROUND:Research on Virtual Reality (VR) based motor rehabilitation for people with multiple sclerosis (MS) is rapidly growing in popularity, although few studies have focused on the upper limb (UL). The aims of this review were to investigate the effect of VR interventions on UL function in people with MS and deter...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102610

    authors: Webster A,Poyade M,Rooney S,Paul L

    更新日期:2020-10-31 00:00:00

  • Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.

    abstract::Fibrinogen is a protein that plays a key role in blood coagulation and thrombosis and it is involved in several inflammatory processes; in multiple sclerosis (MS) may be related with blood-brain barrier (BBB) disruption. We analysed the relationship between plasma fibrinogen levels and the presence of active lesions o...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.09.033

    authors: Miranda Acuña J,Hidalgo de la Cruz M,Ros AL,Tapia SP,Martínez Ginés ML,de Andrés Frutos CD

    更新日期:2017-11-01 00:00:00

  • Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

    abstract::Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2015.04.005

    authors: Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

    更新日期:2015-07-01 00:00:00

  • Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders.

    abstract::The identification of AQP4-IgG, a specific and pathogenic antibody of NMO/SD has led to a broadening of the clinical spectrum of manifestations of NMO/SD including the presence of encephalic symptoms. Lesions are often distributed on peri‑ependymal area and sometimes affected the diencephalon leading to sleep disorder...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2019.101869

    authors: Beigneux Y,Arnulf I,Guillaume-Jugnot P,Leu-Semenescu S,Maillart E,Lubetzki C,Benveniste O,Papeix C

    更新日期:2020-02-01 00:00:00

  • Continuous prediction of secondary progression in the individual course of multiple sclerosis.

    abstract:BACKGROUND:Prediction of the course of multiple sclerosis (MS) was traditionally based on features close to onset. OBJECTIVE:To evaluate predictors of the individual risk of secondary progression (SP) identified at any time during relapsing-remitting MS. METHODS:We analysed a database comprising an untreated MS incid...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2014.04.004

    authors: Skoog B,Tedeholm H,Runmarker B,Odén A,Andersen O

    更新日期:2014-09-01 00:00:00

  • Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.

    abstract:BACKGROUND:The 2015 International Panel for neuromyelitis optica (NMO) spectrum disorders (NMOSD) diagnosis (IPND) criteria was recently proposed. However, because there are no studies evaluating application of the IPND criteria in Latin American populations, we aimed to assess whether these new criteria improve the di...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.01.001

    authors: Carnero Contentti E,Soto de Castillo I,Daccach Marques V,López PA,Antunes Barreira A,Armas E,de Aquino Cruz C,Rubstein A,Lavigne Moreira C,Molina OM,Soto A,Tkachuk V

    更新日期:2018-02-01 00:00:00

  • Improving MS patients' understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial.

    abstract:BACKGROUND:Multiple Sclerosis (MS) patients find it difficult to understand the complex risk-benefit profiles of disease-modifying drugs. An evidence-based protocol was designed to improve patient's understanding of treatment information: Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS). OBJE...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2021.102737

    authors: Reen GK,Silber E,Langdon DW

    更新日期:2021-01-12 00:00:00

  • End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

    abstract:BACKGROUND:Many natalizumab treated patients experience end of dose interval (EDI) symptoms towards the end of the administration cycle. Natalizumab has previously shown to influence cytokine profiles in relapsing remitting MS patients. We hypothesize that EDI symptoms might be explained by variability in serum cytokin...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102020

    authors: Cathérine D,Annelien P,Anne S,Luc A,Liesbeth VH,Gerlo S,Guy L

    更新日期:2020-06-01 00:00:00

  • Does vagotomy protect against multiple sclerosis?

    abstract:OBJECTIVES:To examine the association between vagotomy and multiple sclerosis. METHODS:We conducted a matched cohort study of all patients who underwent truncal or super-selective vagotomy and a comparison cohort, by linking Danish population-based medical registries (1977-1995). Hazard ratios (HRs) for multiple scler...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.04.009

    authors: Sundbøll J,Horváth-Puhó E,Adelborg K,Svensson E

    更新日期:2017-07-01 00:00:00

  • Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

    abstract:BACKGROUND:People with multiple sclerosis (MS) experience symptoms in multiple domains. High-quality patient-reported outcomes (PROs) that assess multiple domains can aid healthcare providers in assessing these symptoms and may support remote disease monitoring. The "SymptoMScreen" PRO correlates with other PROs in MS;...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.031

    authors: Fitzgerald KC,Salter A,Tyry T,Fox RJ,Cutter G,Mowry EM,Marrie RA

    更新日期:2019-04-01 00:00:00

  • Neural cell adhesion molecules in brain plasticity and disease.

    abstract::Neural cell adhesion molecule (NCAM) has been studied extensively. But it is only in recent times that interest in this molecule has shifted to conditions such as Alzheimer's disease, Multiple Sclerosis and Schizophrenia, focusing on its role in neurodegeneration and abnormal neurodevelopment. NCAM is important in neu...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2012.08.002

    authors: Gnanapavan S,Giovannoni G

    更新日期:2013-01-01 00:00:00

  • Cerebral toxoplasmosis in an MS patient receiving Fingolimod.

    abstract::Multiple Sclerosis (MS) is an autoimmune disease in which lymphocytes target putative myelin antigens in the CNS, causing inflammation and neurodegeneration. Fingolimod (FTY720) is an immunosuppressive drug used as a second line therapy for relapsing forms of MS due to its safety profile and good response to treatment...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.05.004

    authors: Enriquez-Marulanda A,Valderrama-Chaparro J,Parrado L,Diego Vélez J,Maria Granados A,Luis Orozco J,Quiñones J

    更新日期:2017-11-01 00:00:00

  • Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.

    abstract:BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102208

    authors: Edgar Patricio CD,Eleanor THG,Francisco José CZ,Gabriela ACM,Hyland AO,Fernando GL,María TA,Beatriz N,Marcos SD,Alfredo GPW

    更新日期:2020-09-01 00:00:00

  • Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls.

    abstract:BACKGROUND:Relapsing-Remitting MS (RRMS) Deep Grey Matter (DGM) 5 year changes were examined using MRI measures of volume, transverse relaxation rate (R2*) and quantitative magnetic susceptibility (QS). By applying Discriminative Analysis of Regional Evolution (DARE), R2* and QS changes from iron and non-iron sources w...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.05.028

    authors: Elkady AM,Cobzas D,Sun H,Seres P,Blevins G,Wilman AH

    更新日期:2019-08-01 00:00:00

  • Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial.

    abstract:BACKGROUND:Cognitive impairment is common in multiple sclerosis (MS), but deficits tend to be more pronounced in progressive MS, negatively impacting daily functional capacity. Despite this, most cognitive rehabilitation (CR) interventions to date have focused on relapsing-remitting MS (RRMS). Moreover, information on ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.101932

    authors: Messinis L,Kosmidis MH,Nasios G,Konitsiotis S,Ntoskou A,Bakirtzis C,Grigoriadis N,Patrikelis P,Panagiotopoulos E,Gourzis P,Malefaki S,Papathanasopoulos P

    更新日期:2020-01-07 00:00:00

  • Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.

    abstract:INTRODUCTION:Italy has been the first European country severely affected by the COVID-19 pandemic. OBJECTIVE:To analyze the incidence of the clinical presentations suggestive for COVID-19 infection among patients with Multiple Sclerosis in the province of Lecco, in the North Italy, the closest province capital to Berg...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102453

    authors: Mantero V,Abate L,Balgera R,Basilico P,Salmaggi A,Cordano C

    更新日期:2020-11-01 00:00:00

  • A case-control study of dietary salt intake in pediatric-onset multiple sclerosis.

    abstract:BACKGROUND:High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. OBJECTIVE:We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-co...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.msard.2016.02.011

    authors: McDonald J,Graves J,Waldman A,Lotze T,Schreiner T,Belman A,Greenberg B,Weinstock-Guttman B,Aaen G,Tillema JM,Hart J,Lulu S,Ness J,Harris Y,Rubin J,Candee M,Krupp LB,Gorman M,Benson L,Rodriguez M,Chitnis T,Mar S

    更新日期:2016-03-01 00:00:00

  • An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report.

    abstract:BACKGROUND:The acute, fulminant type of Multiple Sclerosis (MS), known as Marburg Disease, has been shown to have poor response to conventional acute treatments typically used for demyelinating diseases. METHODS:We report a 20 y/o postpartum female who was consulted to the Neurology service given findings of subacute ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.03.014

    authors: Avila-Ornelas J,Labat E,Alfonso G,Serrano C,Fiorito F

    更新日期:2019-06-01 00:00:00

  • Cross-sectional survey of complementary and alternative medicine used in Oregon and Southwest Washington to treat multiple sclerosis: A 17-Year update.

    abstract:BACKGROUND:In 2001, we conducted a survey on use of complementary and alternative medicine (CAM) in people with multiple sclerosis (pwMS) in Oregon and Southwest Washington to treat their disease. OBJECTIVES, METHODS:In 2018, we administered a revised survey in the same region to describe updated patterns of CAM use i...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102041

    authors: Silbermann E,Senders A,Wooliscroft L,Rice J,Cameron M,Waslo C,Orban A,Chase E,Yadav V,Bourdette D,Spain RI

    更新日期:2020-06-01 00:00:00

  • Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

    abstract:OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The en...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2013.05.003

    authors: Thaera GM,Wingerchuk DM,Carter JL

    更新日期:2014-01-01 00:00:00

  • Neurosarcoidosis as an MS Mimic: The trials and tribulations of making a diagnosis.

    abstract::The clinical presentation of neurosarcoidosis is varied as multiple levels of the neuraxis may be affected. When central nervous system involvement occurs, making an accurate diagnosis of the condition can be challenging, especially given the current definition for definite neurosarcoidosis requires histologic confirm...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2015.06.012

    authors: MacLean HJ,Abdoli M

    更新日期:2015-09-01 00:00:00

  • Efficacy of computer-based cognitive training in neuropsychological performance of patients with multiple sclerosis: A systematic review and meta-analysis.

    abstract:IMPORTANCE:Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by relapses and a progressive course that may lead to accumulation of physical and cognitive disability. Cognitive training interventions seem to improve the cognitive performance of MS patients. The aim of ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.msard.2017.12.017

    authors: Dardiotis E,Nousia A,Siokas V,Tsouris Z,Andravizou A,Mentis AA,Florou D,Messinis L,Nasios G

    更新日期:2018-02-01 00:00:00

  • 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity?

    abstract:BACKGROUND:McDonald criteria for multiple sclerosis (MS) diagnosis were revised in 2017. OBJECTIVE:Aim of our study was to evaluate and compare the sensitivity and specificity of 2017 and 2010 McDonald criteria in patients presenting with an initial demyelinating event (IDE). METHODS:We retrospectively identified pat...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.008

    authors: Gobbin F,Zanoni M,Marangi A,Orlandi R,Crestani L,Benedetti MD,Gajofatto A

    更新日期:2019-04-01 00:00:00

  • Prevalence of multiple sclerosis in Health District III, Murcia, Spain.

    abstract:BACKGROUND:The prevalence of multiple sclerosis (MS) varies throughout the world, and available epidemiological data suggest a progressively increasing prevalence of MS in Spain. The objective of this study was to calculate MS prevalence in Health District III of the autonomous community of Murcia in Spain. METHODS:Th...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.06.003

    authors: Candeliere-Merlicco A,Valero-Delgado F,Martínez-Vidal S,Lastres-Arias Mdel C,Aparicio-Castro E,Toledo-Romero F,Villaverde-González R

    更新日期:2016-09-01 00:00:00

  • CNS demyelination during tofacitinib therapy: First report.

    abstract::Iatrogenic demyelination is a distinct clinical subtype of central nervous system inflammatory disorders. The Janus kinase inhibitor, tofacitinib, is an oral disease-modifying antirheumatic drug that has shown contradictory effects on multiple sclerosis in animal models. In this report, we describe a novel case of rev...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102568

    authors: Massoud F,Ismail II,Al-Hashel JY,Abboud H

    更新日期:2020-11-01 00:00:00

  • Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

    abstract:BACKGROUND:MS imposes a significant burden on patients, caregivers, employers, and the healthcare system. OBJECTIVE:To comprehensively evaluate the US MS burden using nationally representative data from the Medical Expenditure Panel Survey. METHODS:We identified non-institutionalized patients aged ≥18 with MS (ICD-9 ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2013.09.004

    authors: Campbell JD,Ghushchyan V,Brett McQueen R,Cahoon-Metzger S,Livingston T,Vollmer T,Corboy J,Miravalle A,Schreiner T,Porter V,Nair K

    更新日期:2014-03-01 00:00:00

  • Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.

    abstract:BACKGROUND:A high percentage of patients with multiple sclerosis present cognitive alterations. Because 4-aminopyridine improves nerve conduction and efficient synaptic connection could improve cognitive dysfunction. OBJECTIVE:To evaluate the efficacy on cognitive performance and safety of 4-aminopyridine administered...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2018.12.026

    authors: Arreola-Mora C,Silva-Pereyra J,Fernández T,Paredes-Cruz M,Bertado-Cortés B,Grijalva I

    更新日期:2019-02-01 00:00:00

  • The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis.

    abstract:OBJECTIVE:To estimate pooled prevalence of cognitive impairment in neuromyelitis opticaspectrum disorders (NMOSD) cases. METHODS:We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. We also searched the gray literature including references of the included studies, and conference abstracts which were...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2021.102757

    authors: Moghadasi AN,Mirmosayyeb O,Mohammadi A,Sahraian MA,Ghajarzadeh M

    更新日期:2021-01-15 00:00:00